Syndax Pharmaceuticals, Inc. reported $252M of revenue over the trailing twelve months, +223% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $252M (to Q2 2026). Net income: −$221M, trailing twelve months to Q2 2026. Operating margin: −81%, trailing twelve months to Q2 2026. EPS: −$2.51, trailing twelve months to Q2 2026.

SNDXSyndax Pharmaceuticals, Inc.

Healthcare

$16.99+15% 1Y

$16.99

$13.1152 weeks$25.15

SNDX as reported

Syndax Pharmaceuticals, Inc. reported $252M of revenue over the trailing twelve months, +223% on the year before. 9 reported series are charted on this page, each one as filed.

$252M

Revenue, trailing twelve months · to Q2 2026 · +223% against the twelve months before

Net income: −$221M
Net income · −34% year on year · trailing twelve months to Q2 2026
Operating margin: −81%
Operating margin · trailing twelve months to Q2 2026
EPS: −$2.51
EPS · −35% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SNDX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$252M	+223%	Q2 2026
Net income	−$221M	−34%	Q2 2026
EPS	−$2.51	−35%	Q2 2026
Operating margin	−81%	n/a	Q2 2026
Net margin	−91%	n/a	Q2 2026
ROE	−690%	n/a	Q2 2026
ROA	−48%	n/a	Q2 2026
ROIC	−1282%	n/a	Q2 2026
Free cash flow	−$69M	n/a	Q4 2018 · 30 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.